In patients receiving first-line doravirine, median weight gain over 96 weeks was 1.5 kg, a change similar to that seen in adults without HIV infection and in those starting ART with other agents.
Among cis-MSM and transgender women at high risk of HIV infection, initiation of daily oral FTC/TAF for PrEP associated with significantly better BMD, eGFR, and renal tubular function, as measured by urine RBP:Cr and β2M:Cr.
The contribution of PrEP to decline in HIV incidence was 2.1 times larger than treatment as prevention in an analysis considering both interventions.
Final analysis of this phase IIb study observes that oral cabotegravir plus rilpivirine maintenance regimen provides durable virologic suppression.
Among patients initiating dual therapy, virologic suppression rates maintained regardless of stratification by age, sex, race, and baseline HIV-1 RNA level or CD4+ cell count.
Prospective data on birth outcomes demonstrate no increase in rates of spontaneous abortions, stillbirths, neural tube defects, or other congenital anomalies with raltegravir use at conception or during pregnancy.
No patient met criteria for protocol-defined virologic failure or discontinued for lack of efficacy through Week 48.
This small prospective study found that sizeable proportions of MSM (24% to 35%) experienced more than 3% BMD loss in the femur, spine, and hip after 2 years of TDF-based PrEP.
Switching from a TAF-based regimen to DTG/3TC maintains virologic suppression across patient subgroups regardless of patient demographics, disease characteristics, or baseline third agent.
In pooled analysis of 373 treatment-naive and virologically suppressed females, no emergent resistance or discontinuation for renal or bone adverse events was observed.